Stock Price Forecast

Jan. 21, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Advaxis, Inc. chart...

About the Company

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

CEO

Kenneth Berlin

Exchange

OTC MARKETS

Website

www.advaxis.com

$3M

Total Revenue

18

Employees

$14M

Market Capitalization

-0.72

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADXS News

Advaxis Executes Strategic Unregistered Equity Sales

1mon ago, source: Hosted on MSN

Advaxis (ADXS) has released an update to notify the public and investors about the unregistered sales of equity securities. Ayala Pharmaceuticals, Inc. issued $4.0 million in Senior Convertible ...

Advaxis Announces Definitive Agreement with Ayala Pharmaceuticals

1mon ago, source: Hosted on MSN

Advaxis (ADXS) has released an update to notify the public and investors about an entry into a material definitive agreement. Ayala Pharmaceuticals, Inc. has agreed to sell its main assets ...

Advaxis Inc (FAD.BE)

2mon ago, source: Yahoo Finance

BOTHELL, Wash. & MONMOUTH JUNCTION, N.J., February 06, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer ...

Ayala Pharmaceuticals Inc (ADXS)

28d ago, source: Investing

Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Consumer Services, Basic Materials and Industrials sectors led shares lower. At the close in... Investing.com ...

Welcome to Inc.'s Directory of B2B Excellence

4mon ago, source: Inc

They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.

STIHL Inc.

7mon ago, source: Forbes

This company has paid to receive expanded profile features. About STIHL Inc. Virginia-based STIHL Inc. is the U.S. affiliate for the global STIHL group and the manufacturer of the number one ...

Snap Inc Class A

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Apple Inc.

20d ago, source: Wall Street Journal

1 Day AAPL 2.56% DJIA 0.30% S&P 500 1.05% Technology -1.75% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum ...

Advaxis Inc (FAD.SG)

4mon ago, source: Yahoo Finance

BOTHELL, Wash. & MONMOUTH JUNCTION, N.J., February 06, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer ...

Snap Inc.

1mon ago, source: Wall Street Journal

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...